Kolexia
Muret Patrice
Médecine générale
Hôpital Jean-Minjoz
Besançon, France
67 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Infections à VIH Hépatite C Ulcère de la jambe Co-infection Hépatite Hépatite chronique Ulcère Hépatite C chronique Craniopharyngiome

Industries

MSD
11 collaboration(s)
Dernière en 2023
Gilead
11 collaboration(s)
Dernière en 2023
ViiV Healthcare
4 collaboration(s)
Dernière en 2023
agence européenne informatique
2 collaboration(s)
Dernière en 2023

Dernières activités

Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study).
British journal of clinical pharmacology   21 août 2023
Management of a drug-drug interaction between BRAF inhibitors and combined antiretroviral therapy in a HIV-infected patient with craniopharyngioma.
AIDS (London, England)   19 mai 2023
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
The Journal of antimicrobial chemotherapy   03 mars 2023
Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients.
Current HIV research   13 décembre 2021
Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants.
Journal of chemotherapy (Florence, Italy)   26 juin 2021
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America   06 janvier 2021
Surdosage en rilpivirine et cardiotoxicité : vrai risque ou fausse alerte ?
21es Journées Nationales d’Infectiologie   01 septembre 2020
Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice.
Current HIV research   15 juillet 2020
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis: Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)
Essai Clinique (Gilead)   13 février 2019
Development and validation of a simple method for the extraction of human skin melanocytes.
Cytotechnology   21 mars 2018